位置:首页 > 产品库 > Baclofen hydrochloride
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Baclofen hydrochloride
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Baclofen hydrochloride图片
CAS NO:28311-31-1

巴氯芬盐酸盐
Baclofen hydrochloride 是 γ-氨基丁酸 (GABA) 的亲脂性衍生物,是一种口服有效,选择性的代谢型 GABAB受体 (GABABR) 激动剂。Baclofen hydrochloride 可以模拟 GABA 的作用并通过 GABAB受体产生缓慢的突触前抑制。Baclofen hydrochloride 具有高的血脑屏障透过率。Baclofen hydrochloride 有用于肌肉痉挛研究的潜力。
生物活性

Baclofen hydrochloride, a lipophilic derivative of γ-aminobutyric acid (GABA), is an orally active, selective metabotropicGABABreceptor (GABABR)agonist. Baclofen hydrochloride mimics the action of GABA and produces slow presynaptic inhibition through the GABABreceptor. Baclofen hydrochloride has high blood brain barrier penetrance. Baclofen hydrochloride has the potential for muscle spasticity research[1][2][3].

体外研究
(In Vitro)

Baclofen (1, 10 μM; 24 h) hydrochloride causes markedly decreased lactate dehydrogenase (LDH) activity, indicating increased cell viability in wild-type or mutant huntingtin-expressing striatal cells (HD19 or HD43). Baclofen significantly increases chymotrypsin-like proteasome activity and cell viability were in the HD43 cells[3].

体内研究
(In Vivo)

Baclofen (i.p.; 10 μg/g; twice daily for 3 consecutive days) hydrochloride ameliorates motor deficits in YAC128 HD transgenic mice[3].

Animal Model:Wild type (WT) and mutant (MT) male YAC128 mice at 13-18 months of age[3]
Dosage:10 μg/g
Administration:IP; twice daily at 9:00 a.m. and 5:00 p.m., for 3 consecutive days; then single dose on the fourth day at 9:00 a.m
Result:Ameliorated motor deficits in YAC128 HD transgenic mice.
Increased proteasome activity and reduces neuronal intranuclear inclusions (NIIs) in YAC128 HD transgenic mice.
Clinical Trial
分子量

250.12

Formula

C10H13Cl2NO2

CAS 号

28311-31-1

中文名称

巴氯芬盐酸盐; 盐酸巴氯芬

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024